Competing risks and the clinical community: Irrelevance or ignorance?

Statistics in Medicine

Volumn 31, Issue 11-12, 2012, Pages 1089-1097

  Koller, Michael T ^a,b   Raatz, Heike ^a   Steyerberg, Ewout W ^c   Wolbers, Marcel ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

Cause specific hazard; Clinical interpretation; Competing risks; Quality of reporting; Subdistribution hazard

Indexed keywords

AGING; ARTICLE; BIOSTATISTICS; CLINICAL MEDICINE; CLINICAL STUDY; COMPETING RISK; LIFE EXPECTANCY; MEDICAL LITERATURE; METHODOLOGY; RISK; RISK ASSESSMENT; STATISTICAL ANALYSIS; TRANSLATIONAL RESEARCH;

AGED; AGED, 80 AND OVER; AGING; BIOMEDICAL RESEARCH; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MODELS, STATISTICAL; RISK;

EID: 84861182665     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4384     Document Type: Article

References (35)

1. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Medical Care 2010; 48(6 Suppl):S96-S105.
2. Statistics Norway. Life expectancy - remaining years for males and females at selected ages. 1866-2009, 2009. Accessed 14.11.2010.
3. Spillman BC, Lubitz J. The effect of longevity on spending for acute and long-term care. The New England Journal of Medicine 2000; 342(19):1409-1415.
4. Hanchate A, Kronman AC, Young-Xu Y, Ash AS, Emanuel E. Racial and ethnic differences in end-of-life costs: why do minorities cost more than whites? Archives of Internal Medicine 2009; 169(5):493-501.
5. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church T. et al. Mortality results from a randomized prostate-cancer screening trial. The New England Journal of Medicine 2009; 360(13):1310-1319.
6. Wolkewitz M, Vonberg RP, Grundmann H, Beyersmann J, Gastmeier P, Barwolff S. et al. Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Crital Care 2008; 12(2):R44.
7. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statistics in Medicine 2007; 26(11):2389-2430.
8. Andersen PK, Abildstrom SZ, Rosthoj S. Competing risks as a multi-state model. Statistical Methods in Medical Research 2002; 11(2):203-215.
9. Beyersmann J, Latouche A, Buchholz A, Schumacher M. Simulating competing risks data in survival analysis. Statistics in Medicine 2009; 28(6):956-971.
10. Beyersmann J, Schumacher M. Misspecified regression model for the subdistribution hazard of a competing risk. Statistics in Medicine 2007; 26(7):1649-1651.
11. Beyersmann J, Dettenkofer M, Bertz H, Schumacher M. A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards. Statistics in Medicine 2007; 26(30):5360-5369.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94(446):496-509.
13. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. American Journal of Epidemiology 2009; 170(2):244-256.
14. Tsiatis A. A nonidentifiability aspect of the problem of competing risks. Proceedings of the National Academy of Sciences of the United States of America 1975; 72:20-22.
15. Greenland S. Causality theory for policy uses of epidemiological measures. In Summary measures of Population Health, Murray CJL, Salomon JA, Mathers CD, Lopez AD (eds). Harvard University Press/WHO:Cambridge; 2002.291.
16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 1999; 18(6):695-706.
17. Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics 2011; 67(1):39-49.
18. Lau B, Cole SR, Moore RD, Gange SJ. Evaluating competing adverse and beneficial outcomes using a mixture model. Statistics in Medicine 2008; 27(21):4313-4327.
19. Nyangweso P, Hudgens M, Fine JP. Parametric Estimation of Cumulative Incidence Functions for Interval Censored Competing Risks Data, January 2011. The University of North Carolina at Chapel Hill Department of Biostatistics Technical Report Series. Working Paper 19.
20. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Statistics in Medicine 2002; 21(19):2959-2970.
21. Rutten T. Hippocrates commentaries in modern age. Medicina Nei Secoli 2005; 17(2):443-468.
22. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd ed. Lippincott, Williams, & Wilkins: Philadelphia, PA, 19106 USA, 2008.
23. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. Springer: New York, 2008.
24. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology 2009; 20(4):555-561.
25. Ambrogi F, Biganzoli E, Boracchi P. Estimates of clinically useful measures in competing risks survival analysis. Statistics in Medicine 2008; 27(30):6407-6425.
26. Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. Biostatistics 2005; 6(2):227-239.
27. Lubsen J, Hoes A, Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet 2000; 356(9243):1757-1759.
28. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal 1995; 310(6977):452-454.
29. Koller MT, Stijnen T, Steyerberg EW, Lubsen J. Meta-analyses of chronic disease trials with competing causes of death may yield biased odds ratios. Journal of Clinical Epidemiology 2008; 61(4):365-372.
30. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals of Internal Medicine 2009; 150(9):595-603.
31. Gratwohl A, Dohler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet 2008; 372(9632):49-53.
32. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008; 359(21):2195-2207.
33. Koller MT, Bucher HC, Steyerberg EW. Rosuvastatin in patients with elevated C-reactive protein. The New England Journal of Medicine 2009; 360(10):1041-1042.
34. Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction 2006; 101(3):433-440.
35. Grambauer N, Schumacher M, Beyersmann J. Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified. Statistics in Medicine 2010; 29(7-8):875-884.